| scholarly article | Q13442814 |
| P2093 | author name string | David B Clifford | |
| Robert Schmidt | |||
| S Richard Dunham | |||
| P2860 | cites work | Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy | Q24683776 |
| Progressive multifocal leukoencephalopathy: current treatment options and future perspectives | Q26776236 | ||
| Stratification and monitoring of natalizumab-associated progressive multifocal leukoencephalopathy risk: recommendations from an expert group | Q26780412 | ||
| Neurological immune reconstitution inflammatory response: riding the tide of immune recovery | Q28082309 | ||
| Reduction of CD8(+) T lymphocytes in multiple sclerosis patients treated with dimethyl fumarate | Q28388243 | ||
| Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry | Q28555138 | ||
| Treatment of Progressive Multifocal Leukoencephalopathy With Mirtazapine. | Q30249052 | ||
| Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy. | Q30583907 | ||
| PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease Section | Q30613846 | ||
| Progressive multifocal leukoencephalopathy in patients with HIV infection | Q32073645 | ||
| Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project | Q33383576 | ||
| PML-IRIS in patients with HIV infection: clinical manifestations and treatment with steroids | Q33398308 | ||
| Failure of cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team. | Q33502327 | ||
| Progressive multifocal leukoencephalopathy after autologous bone marrow transplantation and alpha-interferon immunotherapy | Q33543030 | ||
| Sustained recovery of progressive multifocal leukoencephalopathy after treatment with IL-2. | Q34466013 | ||
| Efficacy of recombinant human interleukin 7 in a patient with severe lymphopenia-related progressive multifocal leukoencephalopathy | Q34801893 | ||
| Determinants of survival in progressive multifocal leukoencephalopathy | Q35012056 | ||
| Immune reconstitution inflammatory syndrome in natalizumab-associated PML. | Q35215625 | ||
| CRISPR/Cas9 System as an Agent for Eliminating Polyomavirus JC Infection | Q35770584 | ||
| Increased program cell death-1 expression on T lymphocytes of patients with progressive multifocal leukoencephalopathy | Q36103979 | ||
| Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy | Q36234255 | ||
| Interleukin-7 treatment of PML in a patient with idiopathic lymphocytopenia | Q36826947 | ||
| A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes | Q37135539 | ||
| Treatment of natalizumab-associated PML with filgrastim | Q64274762 | ||
| Progressive multifocal leukoencephalopathy | Q70682570 | ||
| Successful treatment of progressive multifocal leukoencephalopathy with low-dose interleukin-2 | Q74015737 | ||
| Progressive multifocal leucoencephalopathy in a patient with systemic lupus erythematosus treated with rituximab | Q80112082 | ||
| Case reports of PML in patients treated for psoriasis | Q85729309 | ||
| High CCR5 expression in natalizumab-associated progressive multifocal leukoencephalopathy immune reconstitution inflammatory syndrome supports treatment with the CCR5 inhibitor maraviroc | Q86564542 | ||
| PML in a patient treated with fumaric acid | Q86649822 | ||
| PML in a patient treated with dimethyl fumarate from a compounding pharmacy | Q86649825 | ||
| PML in a patient without severe lymphocytopenia receiving dimethyl fumarate | Q87077624 | ||
| Progressive multifocal leukoencephalopathy and hematologic malignancies: a single cancer center retrospective review | Q89777446 | ||
| Progressive multifocal leukoencephalopathy: A 25-year retrospective cohort study | Q90286870 | ||
| Tumefactive multiple sclerosis lesions associated with fingolimod treatment: Report of 5 cases | Q90592303 | ||
| Ineffective treatment of PML with pembrolizumab: Exhausted memory T-cell subsets as a clue? | Q90616165 | ||
| Pembrolizumab for progressive multifocal leukoencephalopathy due to primary immunodeficiency | Q90616170 | ||
| Effectiveness of Immune Checkpoint Inhibitors in Transplant Recipients with Progressive Multifocal Leukoencephalopathy | Q90791178 | ||
| Progressive multifocal leukoencephalopathy treated with nivolumab | Q92318946 | ||
| Immune profiling of a patient with alemtuzumab-associated progressive multifocal leukoencephalopathy | Q92966700 | ||
| Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab | Q92999393 | ||
| Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy | Q92999413 | ||
| Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab | Q92999440 | ||
| Progressive multifocal leukoencephalopathy developing after obinutuzumab treatment for chronic lymphocytic leukemia | Q93021725 | ||
| Effect of the CCR5 antagonist maraviroc on the occurrence of immune reconstitution inflammatory syndrome in HIV (CADIRIS): a double-blind, randomised, placebo-controlled trial | Q95823071 | ||
| Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function | Q37180600 | ||
| Maraviroc and JC virus-associated immune reconstitution inflammatory syndrome | Q37313729 | ||
| Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project | Q37568787 | ||
| Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases | Q37714089 | ||
| Evaluation of progressive multifocal leukoencephalopathy treatments in a Spanish cohort of HIV-infected patients: do protease inhibitors improve survival regardless of central nervous system penetration-effectiveness (CPE) score? | Q38065339 | ||
| Progressive multifocal leukoencephalopathy in multiple sclerosis | Q38153637 | ||
| Progressive multifocal leukoencephalopathy therapy | Q38250227 | ||
| Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy? | Q38752797 | ||
| No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML. | Q38754429 | ||
| Identification and characterization of mefloquine efficacy against JC virus in vitro | Q39877627 | ||
| JC virus granule cell neuronopathy in the setting of chronic lymphopenia treated with recombinant interleukin-7. | Q40611943 | ||
| MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance | Q40619670 | ||
| MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. | Q41361912 | ||
| Treating progressive multifocal leukoencephalopathy with interleukin 7 and vaccination with JC virus capsid protein VP1 | Q41741841 | ||
| Immune checkpoint blockade in infectious diseases | Q41921732 | ||
| Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies | Q41926094 | ||
| Treatment of progressive multifocal leukoencephalopathy with interleukin 7. | Q42208209 | ||
| Progressive multifocal leukoencephalopathy after natalizumab discontinuation | Q42255115 | ||
| IL-7 knocks the socs off chronic viral infection | Q42663094 | ||
| A case of progressive multifocal leukoencephalopathy and idiopathic CD4+ lymphocytopenia | Q42877966 | ||
| Is maraviroc beneficial in paradoxical progressive multifocal leukoencephalopathy-immune reconstitution inflammatory syndrome management? | Q43243994 | ||
| Cidofovir in AIDS-associated progressive multifocal leukoencephalopathy: a monocenter observational study with clinical and JC virus load monitoring | Q43716024 | ||
| Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation? | Q43897444 | ||
| A pilot study of cidofovir for progressive multifocal leukoencephalopathy in AIDS. | Q44129718 | ||
| Progressive multifocal leukoencephalopathy associated with ruxolitinib | Q44509111 | ||
| Influence of HAART on the clinical course of HIV-1-infected patients with progressive multifocal leukoencephalopathy: results of an observational multicenter study | Q45064421 | ||
| Anti-John Cunnigham virus antibody prevalence in multiple sclerosis patients: baseline results of STRATIFY-1. | Q45361114 | ||
| Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathy | Q45510977 | ||
| The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. | Q45740735 | ||
| Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. | Q45747990 | ||
| Relation of JC virus DNA in the cerebrospinal fluid to survival in acquired immunodeficiency syndrome patients with biopsy-proven progressive multifocal leukoencephalopathy | Q45749053 | ||
| Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis | Q45814039 | ||
| Progressive multifocal leukoencephalopathy and use of mycophenolate mofetil after kidney transplantation | Q46228478 | ||
| Infectious Entry and Neutralization of Pathogenic JC Polyomaviruses | Q47147327 | ||
| Population-based study of antibody to the human polyomaviruses BKV and JCV and the simian polyomavirus SV40. | Q47763052 | ||
| To do or not to do? plasma exchange and timing of steroid administration in progressive multifocal leukoencephalopathy. | Q47812653 | ||
| Progressive multifocal leukoencephalopathy in 47 HIV-seropositive patients: neuroimaging with clinical and pathologic correlation | Q48312431 | ||
| Analysis of the systemic and intrathecal humoral immune response in progressive multifocal leukoencephalopathy | Q48676578 | ||
| Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era: a nationwide cohort study | Q48828618 | ||
| Brain Magnetic Susceptibility Changes in Patients with Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. | Q52150367 | ||
| Pathogenesis of progressive multifocal leukoencephalopathy and risks associated with treatments for multiple sclerosis: a decade of lessons learned. | Q52587612 | ||
| Progressive multifocal leukoencephalopathy after fingolimod treatment. | Q52718488 | ||
| Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event. | Q55481186 | ||
| Progressive multifocal leukoencephalopathy in transplant recipients | Q56060082 | ||
| Therapeutic use of CCR5 antagonists is supported by strong expression of CCR5 on CD8+ T cells in progressive multifocal leukoencephalopathy-associated immune reconstitution inflammatory syndrome | Q56448571 | ||
| Survival after neuroAIDS: Association with antiretroviral CNS Penetration-Effectiveness score | Q56762687 | ||
| Allogeneic BK Virus-Specific T Cells for Progressive Multifocal Leukoencephalopathy | Q57281351 | ||
| Immune checkpoint inhibitors: recent progress and potential biomarkers | Q60302456 | ||
| IL-7 Engages Multiple Mechanisms to Overcome Chronic Viral Infection and Limit Organ Pathology | Q61727556 | ||
| P921 | main subject | progressive multifocal leukoencephalopathy | Q704930 |
| P577 | publication date | 2020-03-12 | |
| P1433 | published in | Neurotherapeutics | Q15716631 |
| P1476 | title | Treatment of Progressive Multifocal Leukoencephalopathy Using Immune Restoration |
| Q98664276 | Adipocyte Plasma Membrane Protein (APMAP) promotes JC Virus (JCPyV) infection in human glial cells | cites work | P2860 |
Search more.